Cargando…
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Chimeric antigen receptor (CAR) T-cell therapy is a rapidly developing method for adoptive immunotherapy of tumours in recent years. CAR T-cell therapies have demonstrated unprecedented efficacy in the treatment of patients with haematological malignancies. A 90% complete response (CR) rate has been...
Autores principales: | Cai, Qing, Zhang, Mingzhi, Li, Zhaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576929/ https://www.ncbi.nlm.nih.gov/pubmed/33133242 http://dx.doi.org/10.1177/1758835920962963 |
Ejemplares similares
-
The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020) -
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022) -
CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022) -
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021) -
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)